| Not Yet Recruiting | Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the T NCT07376057 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Recruiting | A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Pro NCT07225946 | Janssen Research & Development, LLC | Phase 3 |
| Enrolling By Invitation | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring NCT06788509 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prost NCT06706921 | VA Greater Los Angeles Healthcare System | Phase 4 |
| Recruiting | Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone i NCT06353386 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Recruiting | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer NCT06190899 | Celcuity Inc | Phase 1 / Phase 2 |
| Recruiting | Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer NCT05743621 | Weill Medical College of Cornell University | Phase 1 |
| Completed | A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castr NCT05968599 | Pfizer | — |
| Recruiting | HTL0039732 in Participants With Advanced Solid Tumours NCT05944237 | Cancer Research UK | Phase 1 / Phase 2 |
| Recruiting | Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide i NCT05393791 | Leiden University Medical Center | Phase 2 |
| Completed | Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) NCT05520138 | Pfizer | — |
| Terminated | A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastat NCT05169684 | Bristol-Myers Squibb | Phase 2 |
| Unknown | TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate NCT05156450 | West China Hospital | Phase 2 |
| Unknown | Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy NCT05902247 | Erasmus Medical Center | Phase 1 |
| Recruiting | 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate NCT04868604 | Clarity Pharmaceuticals Ltd | Phase 1 / Phase 2 |
| Recruiting | Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer NCT04597411 | Endocyte | Phase 1 |
| Completed | Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer NCT04717154 | Radboud University Medical Center | Phase 2 |
| Completed | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer NCT04381832 | Arcus Biosciences, Inc. | Phase 1 / Phase 2 |
| Terminated | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRP NCT04249947 | Poseida Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Character NCT04962919 | Latin American Cooperative Oncology Group | — |
| Recruiting | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas NCT04104776 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects NCT03927391 | Radboud University Medical Center | Phase 4 |
| Completed | Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of NCT03822845 | Michael Graham PhD, MD | Phase 2 / Phase 3 |
| Completed | A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Trea NCT03563014 | Bayer | — |
| Active Not Recruiting | A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cance NCT03431350 | Janssen Research & Development, LLC | Phase 2 |
| Completed | 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer NCT03389451 | Michael Graham PhD, MD | Phase 2 / Phase 3 |
| Completed | 68Ga PSMA in Preprostatectomy Patients NCT03388346 | Michael Graham PhD, MD | Phase 2 / Phase 3 |
| Withdrawn | Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients NCT03173859 | University of Athens | Phase 2 |
| Withdrawn | Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review St NCT03325127 | Bayer | — |
| Completed | Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer ) NCT02899104 | Bayer | — |
| Completed | A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer NCT03017417 | Sheffield Teaching Hospitals NHS Foundation Trust | N/A |
| Completed | A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic NCT03016312 | Hoffmann-La Roche | Phase 3 |
| Withdrawn | A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunoth NCT02906605 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases NCT02803437 | Bayer | — |
| Active Not Recruiting | A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrom NCT02592317 | Aragon Pharmaceuticals, Inc. | Phase 1 |
| Completed | Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participa NCT02625857 | Janssen Research & Development, LLC | Phase 1 |
| Completed | Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mC NCT02450812 | Bayer | — |
| Completed | BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) NCT02204072 | Boehringer Ingelheim | Phase 1 |
| Completed | A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer NCT02162836 | Janssen Pharmaceutical K.K. | Phase 1 |
| Terminated | Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer NCT02057666 | Ipsen | Phase 3 |
| No Longer Available | 68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly) NCT04854369 | Tulane University | — |